“‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata

Journal of Patient-Reported Outcomes

Table 2 Sample characteristics

Sample characteristic	N (%)(N = 45)
Years since diagnosis, mean [range]	11.8 [1–47]
SALT score^a, mean [range]	67.2 [0–100]
Current treatment, n (%)^b
JAKi	15 (33)
Other treatment(s)	7 (16)
Unknown, either JAKi or placebo^c	2 (4)
No treatment	23 (51)
Gender, n (%)
Male	19 (42)
Female	26 (58)
Age, mean [range]	33.3 [15–72]
Ethnicity/race, n (%)
Asian	9 (20)
Black or African American	2 (4)
White	25 (56)
Hawaiian or Pacific Islander	1 (2)
Hispanic	5 (11)
Other	3 (7)
Country, n (%)
United States	42 (93)
Canada	3 (7)
Education, highest certificate achieved
No high school diploma	9 (20)
High school diploma or equivalent	15 (33)
Associate’s degree	2 (4)
Bachelor’s degree or higher	19 (42)

Abbreviations: JAKi Janus kinase inhibitors, for example tofacitinib, SALT Severity of Alopecia Tool
^aSALT scores were clinician-reported and were calculated within a mean 0.6 months of the interview (range 0–7 months)
^bNon-mutually exclusive. Other treatments include Biotin Forte with zinc (n = 1), Clobetasol 0.05% ointment (n = 2), Diphenylcyclopropenone (n = 2), Excimer (n = 1), Intralesional Kenalog (n = 3), Luxiq foam (n = 1), Rogaine (n = 1), Slow-release iron (n = 1), Vitamin E (n = 1)
^cTwo patients were in a clinical trial and it was unknown if they were receiving JAKi or placebo
Note: due to rounding some percentages may not total 100%